Investigation and Treatment of Ocular Motor Disorders

眼部运动障碍的调查和治疗

基本信息

  • 批准号:
    7177462
  • 负责人:
  • 金额:
    $ 15.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1986
  • 资助国家:
    美国
  • 起止时间:
    1986-12-01 至 2010-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The long-term objectives of the proposed research are: (1) to learn more about human ocular motor disorders that impair vision during everyday activities; (2) to apply insights from basic science to better understand clinical problems (a translational approach); and (3) to appraise therapeutic measures for abnormal eye movements and so restore clear vision. There are five specific aims, which grow out of prior studies: The first project addresses the pathogenesis of disorders such as opsoclonus, and models that attribute these ocular oscillations to either cerebellar or brainstem mechanisms. The second project investigates the velocity profiles of rapid eye movements (saccades), which are disrupted in certain disorders affecting the brainstem and cerebellum due to premature termination of these movements. The third project concerns the way in which saccades and vergence movements interact during natural shifts of the fixation point. Using a novel paradigm, it is possible to dissociate in time the saccadic and vergence components, and thus systematically study their interaction. The fourth project addresses how vestibular eye movements are suppressed while viewing a near, head fixed target (as in reading while walking). The goal is to better understanding disability for such tasks in patients with disorders of vestibular or visually mediated eye movements. The fifth project is a crossover evaluation of memantine and gabapentin as treatment for acquired forms of nystagmus. Gabapentin suppresses acquired nystagmus and improves vision in some patients, but side-effects such as ataxia limit the dosage tolerated. Memantine is also reported to suppress pendular nystagmus and improve vision in multiple sclerosis (MS), but no double-masked trial has been performed. The research strategies are (1) to relate reliable measurements of eye movements to visual complaints of patients during natural behaviors; (2) to use measurements of normal and abnormal eye movements to test mathematical models that are biologically plausible; and (3) to evaluate new treatments of disorders of ocular motility using controlled trials. Thus, these projects will provide new information on the pathogenesis and treatment of a range of common disorders of eye movements that disrupt clear vision.
描述(由申请人提供):拟议研究的长期目标是:(1)更多地了解日常活动中损害视力的人类眼部运动障碍; (2) 应用基础科学的见解来更好地理解临床问题(转化方法); (3) 评估眼球运动异常的治疗措施,从而恢复清晰的视力。有五个具体目标,源于先前的研究:第一个项目解决了眼阵挛等疾病的发病机制,以及将这些眼部振荡归因于小脑或脑干机制的模型。第二个项目研究快速眼球运动(眼跳)的速度曲线,在影响脑干和小脑的某些疾病中,由于这些运动的过早终止,这种速度曲线会受到干扰。第三个项目涉及注视点自然移动期间眼跳和辐散运动相互作用的方式。使用新颖的范式,可以及时分离扫视和辐散成分,从而系统地研究它们的相互作用。第四个项目解决了在观看近处的头部固定目标(如步行时阅读)时如何抑制前庭眼球运动。目标是更好地了解患有前庭或视觉介导的眼球运动障碍的患者无法完成此类任务。第五个项目是美金刚和加巴喷丁治疗获得性眼球震颤的交叉评估。加巴喷丁可抑制获得性眼球震颤并改善某些患者的视力,但共济失调等副作用限制了耐受剂量。据报道,美金刚还可抑制多发性硬化症 (MS) 患者的摆动性眼球震颤并改善视力,但尚未进行双盲试验。研究策略是(1)将可靠的眼球运动测量与患者在自然行为过程中的视觉抱怨联系起来; (2) 使用正常和异常眼球运动的测量来测试生物学上合理的数学模型; (3) 通过对照试验评估眼部运动障碍的新疗法。因此,这些项目将提供有关破坏清晰视力的一系列常见眼球运动疾病的发病机制和治疗的新信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD JOHN LEIGH其他文献

RICHARD JOHN LEIGH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD JOHN LEIGH', 18)}}的其他基金

OCULAR MOTOR DISORDERS
眼部运动障碍
  • 批准号:
    2160862
  • 财政年份:
    1986
  • 资助金额:
    $ 15.29万
  • 项目类别:
Investigation and Treatment of Ocular Motor Disorders
眼部运动障碍的调查和治疗
  • 批准号:
    6863043
  • 财政年份:
    1986
  • 资助金额:
    $ 15.29万
  • 项目类别:
Investigation and Treatment of Ocular Motor Disorders
眼部运动障碍的调查和治疗
  • 批准号:
    8215703
  • 财政年份:
    1986
  • 资助金额:
    $ 15.29万
  • 项目类别:
Investigation and Treatment of Ocular Motor Disorders
眼部运动障碍的调查和治疗
  • 批准号:
    7583958
  • 财政年份:
    1986
  • 资助金额:
    $ 15.29万
  • 项目类别:
INVESTIGATION AND TREATMENT OF OCULAR MOTOR DISORDERS
眼运动疾病的调查和治疗
  • 批准号:
    3263313
  • 财政年份:
    1986
  • 资助金额:
    $ 15.29万
  • 项目类别:
INVESTIGATION AND TREATMENT OF OCULAR MOTOR DISORDERS
眼运动疾病的调查和治疗
  • 批准号:
    6329498
  • 财政年份:
    1986
  • 资助金额:
    $ 15.29万
  • 项目类别:
INVESTIGATION AND TREATMENT OF OCULAR MOTOR DISORDERS
眼运动疾病的调查和治疗
  • 批准号:
    2160865
  • 财政年份:
    1986
  • 资助金额:
    $ 15.29万
  • 项目类别:
INVESTIGATION AND TREATMENT OF OCULAR MOTOR DISORDERS
眼运动疾病的调查和治疗
  • 批准号:
    3263311
  • 财政年份:
    1986
  • 资助金额:
    $ 15.29万
  • 项目类别:
INVESTIGATION AND TREATMENT OF OCULAR MOTOR DISORDERS
眼运动疾病的调查和治疗
  • 批准号:
    2838280
  • 财政年份:
    1986
  • 资助金额:
    $ 15.29万
  • 项目类别:
INVESTIGATION AND TREATMENT OF OCULAR MOTOR DISORDERS
眼运动疾病的调查和治疗
  • 批准号:
    6476315
  • 财政年份:
    1986
  • 资助金额:
    $ 15.29万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 15.29万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 15.29万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 15.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 15.29万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 15.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 15.29万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 15.29万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 15.29万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 15.29万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 15.29万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了